Its genetic inactivation characterizes more than 50% of human cancers and its functional impairment occurs in most of the remaining part, highlighting the “reactivation of p53” as a treatment option potentially effective for an extremely broad range of human cancers. The gene discussed is TP53; the disease is cancer.